OncologyProstatic Neoplasms

Prostate Cancer in the Radioligand Era: Pluvicto Expands

Label expansion triples the eligible population and the infrastructure race begins

SR-2026-008

EditorMara Voss

CopywritersEditorial Team

Coming Soon

Prostate Cancer in the Radioligand Era: Pluvicto Expands

Label expansion triples the eligible population and the infrastructure race begins

Why We Are Covering This

Pluvicto's March 2025 label expansion tripled its eligible patient population, and PSMAddition data now positions radioligand therapy earlier in the prostate cancer treatment sequence than the initial approval ever indicated.

What to Expect

You will leave knowing how PSMA testing requirements affect patient selection, how to sequence RLT against ARPIs and standard of care, and what supply chain and dosimetry constraints currently limit access in practice.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-00807/26

Solid Tumors

Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging

Insights from the bowhead whale's exceptional lifespan and cancer resistance point to novel genetic pathways for human anti-aging and oncology research.

Prostatic Neoplasms

Prostate Care: Balancing Immediate Relief with Long-Term Retreatment

Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.

Breast Neoplasms

Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy

A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.

Breast Neoplasms

Giredestrant Improves Breast Cancer Survival Regardless of Menopause

Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.

Prostate Cancer in the Radioligand Era: Pluvicto Expands

Prostate Cancer in the Radioligand Era: Pluvicto Expands

Be first when this report publishes

Related Articles